Piper Sandler Maintains Overweight on Karyopharm Therapeutics, Lowers Price Target to $5
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Christopher Raymond has maintained an Overweight rating on Karyopharm Therapeutics (NASDAQ:KPTI) but lowered the price target from $7 to $5.
November 03, 2023 | 9:16 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Piper Sandler has maintained an Overweight rating on Karyopharm Therapeutics but lowered the price target from $7 to $5.
The lowering of the price target by Piper Sandler from $7 to $5 indicates a potential decrease in the short-term value of Karyopharm Therapeutics' stock. However, the maintained Overweight rating suggests that the analyst still sees potential in the company's long-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100